CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 1 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,291,437 | -29.2% | 517,244 | +3.0% | 0.00% | -40.0% |
| Q2 2023 | $15,958,039 | +34.4% | 501,983 | +3.1% | 0.01% | +25.0% |
| Q1 2023 | $11,877,516 | -22.4% | 486,983 | +0.3% | 0.00% | -20.0% |
| Q4 2022 | $15,307,750 | +15.8% | 485,344 | +3.8% | 0.01% | 0.0% |
| Q3 2022 | $13,220,000 | +26.4% | 467,786 | +18.3% | 0.01% | +25.0% |
| Q2 2022 | $10,457,000 | -19.8% | 395,485 | +6.2% | 0.00% | 0.0% |
| Q1 2022 | $13,044,000 | +10.8% | 372,561 | +2.6% | 0.00% | +33.3% |
| Q4 2021 | $11,773,000 | +13.4% | 363,120 | +3.2% | 0.00% | 0.0% |
| Q3 2021 | $10,379,000 | +61.1% | 351,808 | +39.9% | 0.00% | +50.0% |
| Q2 2021 | $6,444,000 | +173.3% | 251,493 | +46.5% | 0.00% | +100.0% |
| Q1 2021 | $2,358,000 | -14.7% | 171,670 | +3.0% | 0.00% | 0.0% |
| Q4 2020 | $2,765,000 | – | 166,710 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,713,470,000 | 41.39% |
| Perceptive Advisors | 6,511,727 | $184,021,000 | 5.34% |
| Finepoint Capital LP | 536,901 | $15,173,000 | 4.99% |
| Artal Group S.A. | 2,000,000 | $56,520,000 | 2.41% |
| Rock Springs Capital Management LP | 2,499,148 | $70,626,000 | 1.82% |
| Ikarian Capital, LLC | 178,100 | $5,033,000 | 1.00% |
| Hood River Capital Management LLC | 896,572 | $25,337,000 | 0.97% |
| Frazier Life Sciences Management, L.P. | 393,000 | $11,106,000 | 0.86% |
| HighVista Strategies LLC | 23,611 | $667,000 | 0.38% |
| FEDERATED HERMES, INC. | 3,313,333 | $93,635,000 | 0.27% |